UPDATE:H.C. Wainwright Reiterates Buy On Biogen, Raises Tgt To $335 Notes 'In light of the new analysis from the aducanumab Phase 3 trials and plans for BLA submission based on discussions with the FDA, we raised our probability of success to 15%' From 0%
Benzinga_Newsdesk